FUTURE PERSPECTIVES The emergence of SGLT2 inhibitors and GLP1 receptor agonists represents a major advancement in the management of DKD
Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus
Carrying extra weight places ongoing strain on multiple body systems, increasing the risk of conditions such as cardiovascular disease, high blood pressure, type 2 diabetes and other metabolic disorders, liver disease, and joint health
These types of injections are sometimes given in the abdominal area to make use of the fatty tissue beneath the skin, similar to how insulin is administered
Cel Longev , 9084643
Its version without Drug Affinity Complex (DAC) typically has a shorter half-life measured in hours, while the DAC-modified version can remain active for several days because the modification slows degradation since the DAC component allows the peptide to bind to albumin in the bloodstream, extending circulation time